ABT-263 (Navitoclax) is a potent orally bioavailable SMI that is structurally related to ABT-737. ABT-263 disrupts Bcl-2 – Bcl-XL interactions with pro-apoptotic proteins .
More Information Supplier PageMethotrexate is a cytotoxic agent that inhibits thymidylate synthetase and de novo purine synthesis.
More Information Supplier PageMethotrexate is a cytotoxic agent that inhibits thymidylate synthetase and de novo purine synthesis.
More Information Supplier PageMethotrexate is a cytotoxic agent that inhibits thymidylate synthetase and de novo purine synthesis.
More Information Supplier PageMethotrexate is a cytotoxic agent that inhibits thymidylate synthetase and de novo purine synthesis.
More Information Supplier PageAbiraterone (CB-7598) inhibits 17 ??-hydroxylase/C17,20 lyase (CYP17A1), an enzyme which is expressed in testicular, adrenal, and prostatic tumor tissues.
More Information Supplier PageAbiraterone (CB-7598) inhibits 17 ??-hydroxylase/C17,20 lyase (CYP17A1), an enzyme which is expressed in testicular, adrenal, and prostatic tumor tissues.
More Information Supplier PageAbiraterone (CB-7598) inhibits 17 ??-hydroxylase/C17,20 lyase (CYP17A1), an enzyme which is expressed in testicular, adrenal, and prostatic tumor tissues.
More Information Supplier PageABT-263 (Navitoclax) is a potent orally bioavailable SMI that is structurally related to ABT-737. ABT-263 disrupts Bcl-2 – Bcl-XL interactions with pro-apoptotic proteins .
More Information Supplier PageABT-263 (Navitoclax) is a potent orally bioavailable SMI that is structurally related to ABT-737. ABT-263 disrupts Bcl-2 – Bcl-XL interactions with pro-apoptotic proteins .
More Information Supplier Page
